Latest CLL News


The MCL Exchange: New Horizons in MCL: Clinical Advances and Trials


Are you aware of a new 1L treatment option for eligible MCL patients? Hear from Dr Faye Sharpley, Dr David Lewis & Dr Matthew Wilson.

Found this useful? You might also be interested in:

 

The CLL Exchange:
UK real-world evidence in CLL

The CLL Exchange:
Managing Cardiovascular
Comorbidities and Complications
in CLL

Adverse events should be reported

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.

September 2025 I GB-69434